U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT06856941) titled 'CsDCS on Functional Mobility in Parkinsons Disease' on Feb. 26.
Brief Summary: Parkinsons disease is a progressive neurological disorder marked by a decline in the efficacy of dopaminergic synapses in the nigrostriatal pathway, causing motor disturbances. Resting tremor, bradykinesia, and muscle rigidity are the most prominent motor features. These factors result in gait impairments, including slowness and freezing. The primary treatment for the disease is medication. However, while medication does reduce motor symptoms, prolonged usage may lead to an increase of dyskinesias and a worsening of a patients clinical condition. Thus, al...